Mental health problems (MHP) in children and adolescents (CA) are common. This longitudinal study analyzed the prevalence, course, and persistence of MHP over 10years from childhood into adolescence based on a sample from the Future Family project (N = 230).
 
  At the pre-assessment point the children were on average 5 (SE = 1) and the mothers 35 (SE = 5) years old. Descriptive methods, Chi
  -tests, binary logistic regression, and different analytical approaches (number chains, transition probability) were used.
 
  Approximately 24% of the CA suffered from borderline clinical or clinically relevant MHP. The largest proportion of the sample was stable healthy (70%), whereas 15% of the CA showed chronic mentally ill, 8% transient, 4% negative and 4% positive courses. The mental health of the mother proved to be a decisive predictor for chronic mentally ill courses. Short-term persistence rates ranged between 60 and 70% from one assessment point to the next one. On the other hand, long-term persistence rates (from childhood into adolescence) were lower (51-59%).
 
  One in seven children in this sample suffered from chronic MHP, while only one third of the CA in Germany with clinically relevant MHP take advantage of psychological or psychiatric care. Prevention programs should be considered as an effective and economic approach to reduce childhood suffering in Germany.
 One in seven children in this sample suffered from chronic MHP, while only one third of the CA in Germany with clinically relevant MHP take advantage of psychological or psychiatric care. Prevention programs should be considered as an effective and economic approach to reduce childhood suffering in Germany.Recently, the outbreaks of hydropericardium-hepatitis syndrome (HHS) caused by the highly pathogenic fowl adenovirus serotype 4 (FAdV-4) have resulted in huge economic losses to the poultry industry globally. Although several inactivated or subunit vaccines have been developed against FAdV-4, live-attenuated vaccines for FAdV-4 are rarely reported. In this study, a recombinant virus FA4-EGFP expressing EGFP-Fiber-2 fusion protein was generated by the CRISPR/Cas9 technique. Although FA4-EGFP shows slightly lower replication ability than the wild type (WT) FAdV-4, FA4-EGFP was significantly attenuated in vivo compared with the WT FAdV-4.  https://www.selleckchem.com/products/bpv-hopic.html  Chickens infected with FA4-EGFP did not show any clinical signs, and all survived to 14 day post-infection (dpi), whereas those infected with FAdV-4 showed severe clinical signs with HHS and all died at 4 dpi. Besides, the inoculation of FA4-EGFP in chickens provided efficient protection against lethal challenge with FAdV-4. Compared with an inactivated vaccine, FA4-EGFP induced neutralizing antibodies with higher titers earlier. All these data not only provide a live-attenuated vaccine candidate against the highly pathogenic FAdV-4 but also give a potential insertion site for developing FAdV-4-based vaccine vectors for delivering foreign antigens.
  In the urgent campaign to develop therapeutics against SARS-CoV-2, natural products have been an important source of new lead compounds.
 
  We herein identified two natural products, ginkgolic acid and anacardic acid, as inhibitors using a high-throughput screen targeting the SARS-CoV-2 papain-like protease (PL
  ). Moreover, our study demonstrated that the two hit compounds are dual inhibitors targeting the SARS-CoV-2 3-chymotrypsin-like protease (3CL
  ) in addition to PL
  . A mechanism of action study using enzyme kinetics further characterized the two compounds as irreversible inhibitors against both 3CL
  and PL
  . Significantly, both identified compounds inhibit SARS-CoV-2 replication in vitro at nontoxic concentrations.
 
  Our finding provides two novel natural products as promising SARS-CoV-2 antivirals.
 Our finding provides two novel natural products as promising SARS-CoV-2 antivirals.The proportion of asymptomatic carriers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains elusive and the potential benefit of systematic screening during the SARS-CoV-2-pandemic is controversial. We investigated the proportion of asymptomatic inpatients who were identified by systematic screening for SARS-CoV-2 upon hospital admission. Our analysis revealed that systematic screening of asymptomatic inpatients detects a low total number of SARS-CoV-2 infections (0.1%), questioning the cost-benefit ratio of this intervention. Even when the population-wide prevalence was low, the proportion of asymptomatic carriers remained stable, supporting the need for universal infection prevention and control strategies to avoid onward transmission by undetected SARS-CoV-2-carriers during the pandemic.Staphylococcus delphini is one of the most common pathogens isolated from mink infections, especially dermatitis. Tylosin (TYL) is used frequently against these infections, although no evidence-based treatment regimen exists. This study aimed to explore the dosage of TYL for infections caused by S. delphini in mink. Two animal experiments with a total of 12 minks were conducted to study the serum pharmacokinetic (PK) characteristics of TYL in mink after 10 mg/kg IV and oral dosing, respectively. The concentration of TYL in serum samples collected before and eight times during 24 h after TYL administration was quantitated with liquid chromatography quadrupole time-of-flight mass spectrometry, and the TYL disposition was analyzed using non-linear mixed effect analysis. The pharmacodynamics (PD) of TYL against S. delphini were studied using semi-mechanistic modeling of in vitro time-kill experiments. PKPD modeling and simulation were done to establish the PKPD index and dosage regimen. The disposition of TYL was described by a two-compartmental model. The area under the free concentration-time curve of TYL over the minimum inhibitory concentration of S. delphini (fAUC/MIC) was determined as PKPD index with breakpoints of 48.9 and 98.7 h for bacteriostatic and bactericidal effect, respectively. The calculated daily oral dose of TYL was 2378 mg/kg, which is 238-fold higher than the currently used TYL oral dosage regimen in mink (10 mg/kg). Accordingly, sufficient TYL concentrations are impossible to achieve in mink plasma, and use of this drug for extra-intestinal infections in this animal species must be discouraged.